Cargando…

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma

CD9 is involved in cell growth, adhesion and motility and its expression is reported to be of prognostic significance in various types of human malignancies. We found increased cell migration in the mesothelioma cell lines MSTO-211H and TUM1 following in vitro shRNA-mediated knockdown of CD9 express...

Descripción completa

Detalles Bibliográficos
Autores principales:	AMATYA, VISHWA JEET, TAKESHIMA, YUKIO, AOE, KEISUKE, FUJIMOTO, NOBUKAZU, OKAMOTO, TOSHIHIRO, YAMADA, TAKETO, KISHIMOTO, TAKUMI, MORIMOTO, CHIKAO, INAI, KOUKI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583601/ https://www.ncbi.nlm.nih.gov/pubmed/23128478 http://dx.doi.org/10.3892/or.2012.2116

Ejemplares similares

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014)

Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
por: Kushitani, Kei, et al.
Publicado: (2018)

Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G(1) cell cycle arrest
por: Kambara, Takahiro, et al.
Publicado: (2022)

Physician requests by patients with malignant pleural mesothelioma in Japan
por: Nagamatsu, Yasuko, et al.
Publicado: (2019)

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
por: Nakagawa, Kazuhiko, et al.
Publicado: (2021)

Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor
por: Naka, Tomoaki, et al.
Publicado: (2022)

Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study
por: Nagamatsu, Yasuko, et al.
Publicado: (2018)

Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27(Kip1)
por: Endo, Ihiro, et al.
Publicado: (2022)

miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma
por: Suzuki, Rui, et al.
Publicado: (2018)

Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1
por: Fujii, Yutaro, et al.
Publicado: (2022)

MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung
por: Mawas, Amany Sayed, et al.
Publicado: (2018)

Clinical, Radiological, and Pathological Investigation of Asbestosis
por: Kishimoto, Takumi, et al.
Publicado: (2011)

Foreign body granuloma mimicking recurrence of malignant pleural mesothelioma
por: Nakasuka, Takamasa, et al.
Publicado: (2015)

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
por: Yamamoto, J, et al.
Publicado: (2014)

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
por: Hayashi, Mutsumi, et al.
Publicado: (2016)

An appropriate choice for immunotherapy in malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2020)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Metachronous Double Pituitary Adenoma with Altered Transcriptional Factor Profile: A Case Report and Literature Review
por: TAGUCHI, Akira, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Spare the lung: surgical treatment approach for malignant pleural mesothelioma
por: Fujimoto, Nobukazu
Publicado: (2023)

Phrenic Nerve Paralysis as the Initial Presentation in Pleural Sarcomatoid Mesothelioma
por: Makimoto, Go, et al.
Publicado: (2014)

Effects of K‐ras Gene Mutations in the Development of Lung Lesions Induced by 4‐(N‐ Methyl‐N‐nitrosamino)‐1‐(3‐pyridyl)‐1‐butanone in A/J Mice
por: Kawano, Ryoji, et al.
Publicado: (1996)

CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells
por: Okamoto, Toshihiro, et al.
Publicado: (2014)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Isolated Neurohypophysial Sarcoidosis Involving the Cavernous Sinus Mimicking a Malignant Tumor
por: KINOSHITA, Yasuyuki, et al.
Publicado: (2022)

Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
por: Tanaka, Takaaki, et al.
Publicado: (2022)

Role of Point Mutation of the K‐ras Gene in Tumorigenesis of B6C3F(1) Mouse Lung Lesions Induced by Urethane
por: Kawano, Ryoji, et al.
Publicado: (1995)

Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung
por: Kai, Yuichiro, et al.
Publicado: (2021)

Clinical Investigation of Benign Asbestos Pleural Effusion
por: Fujimoto, Nobukazu, et al.
Publicado: (2015)

Metastatic Malignant Lymphoma Mimicking Cerebral Toxoplasmosis with the “Target Sign”
por: Ueno, Hiroki, et al.
Publicado: (2018)

Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
por: Kishimoto, Takumi, et al.
Publicado: (2019)

Down‐regulation of KAI1 Messenger RNA Expression Is Not Associated with Loss of Heterozygosity of the KAI1 Gene Region in Lung Adenocarcinoma
por: Tagawa, Kohei, et al.
Publicado: (1999)

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
por: Doonan, Bently P., et al.
Publicado: (2017)

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue
por: Hatano, Ryo, et al.
Publicado: (2014)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Quantitative Risk Assessment of Carcinogenicity of Urethane (Ethyl Carbamatc) on the Basis of Long‐term Oral Administration to B6C3F(1) Mice
por: Inai, Kouki, et al.
Publicado: (1991)

p16/CDKN2 Gene and p53 Gene Alterations in Japanese Non‐smoking Female Lung Adenocarcinoma
por: Takeshima, Yukio, et al.
Publicado: (1996)

Improved differentiation between high- and low-grade gliomas by combining dual-energy CT analysis and perfusion CT
por: Kaichi, Yoko, et al.
Publicado: (2018)

Effect of bevacizumab against cystic components of brain tumors
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019)

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
por: Nishida, Hiroko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0a67b649118v65t679kbtuuh72